Jagsonpal Pharmaceuticals has scheduled a conference call with analysts and investors to discuss its financial results for the first quarter of FY27. The meeting is set to take place on July 30, 2026, at 2:30 PM IST, as part of the company's investor engagement activities.

The discussion will be led by the company's senior management, including Managing Director Manish Gupta, Chief Operating Officer Amrut Medhekar, and Chief Financial Officer Nirav Vora. The event is being hosted by Go India Advisors.

Conference Call Details

Participants are required to pre-register to avoid wait time and join using the Diamond Pass facility. The company has advised attendees to dial in at least 5 to 10 minutes prior to the scheduled start time to ensure timely connection.

For further information regarding the conference call, investors may contact Soumya Chhajed or Sheetal Khanduja via email at soumya@goindiaadvisors.com and sheetal@goindiaadvisors.com , respectively.

Jagsonpal Pharmaceuticals Ltd has successfully completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited. The transaction, finalized on July 17, 2026, marks the conclusion of the acquisition process that was initially proposed to the stock exchanges last month.

The company had previously intimated the exchanges regarding the proposed acquisition on June 29, 2026. Subsequent updates regarding the progress of the deal were provided on July 7, 2026, and July 8, 2026. With the latest disclosure, Jagsonpal Pharmaceuticals Ltd confirmed that the purchase of the majority stake has been fully executed.

Transaction Details

The acquisition involves the purchase of an 85% equity shareholding in Aequitas Healthcare Private Limited. This strategic move expands Jagsonpal Pharmaceuticals Ltd's portfolio through the addition of a new entity under its corporate structure.

Regulatory Disclosures

The disclosure was made to the BSE Ltd and the National Stock Exchange of India Ltd in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was submitted by Pratham Rawal, the Company Secretary & Compliance Officer of Jagsonpal Pharmaceuticals Ltd.